Apr, 2021

Global
News / General News
Astellas’ Efforts Against the Spread of the Coronavirus Disease (COVID-19)
Our heartfelt sympathy goes out to the people who have been affected by the Coronavirus Disease (COVID-19). With the continuing spread of COVID-19, we are, as part of our mission as a pharmaceutical company, taking various actions and measures to contribute to securing the safety of patients and alleviating strain on healthcare resources. The following are our activities and status to date in...
Read More
Global
News / Press Releases
Change of Directors
Read More
Global
News / IR
Posted Financial Results for FY2020
Read More
Global
News / Press Releases
Notice Regarding Impairment Loss for Investigational Gene Therapy AT132 and the Differences Between Financial Forecasts and Actual Results for the Fiscal Year Ended March 31, 2021
TOKYO, April 27, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it booked an impairment loss in the fourth quarter of the fiscal year ended March 31, 2021 (April 1, 2020 to March 31, 2021) and that there are differences between the financial forecasts (Full basis), which were reported on October 30, 2020, and the actual results...
Read More
Global
News / General News
Launch of the IP Principles for Advancing Cures and Therapies (IP PACT)
On 26 April, World Intellectual Property Day, 2021, over 25 members of the innovative biopharmaceutical industry and industry associations, under the umbrella of INTERPAT *1 have launched the “IP PACT *2 : IP Principles for Advancing Cures and Therapies”. Proudly, Astellas is one of the companies that has signed on to the IP PACT. On the same day, to support and announce the launch of this...
Read More

May, 2024

Global
News / Press Releases
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, “Poseida”) today announced that Xyphos Biosciences, Inc., (a wholly...
Read More

Apr, 2024

Global
News / Press Releases
Change in Definition of Core Basis in Financial Results
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at the meeting of the Board of Directors held today, it decided to change the definition of core basis in consolidated financial statements from the fiscal year 2024 (FY2024) ending March 31, 2025 onward. Astellas has been applying International Financial Reporting Standards...
Read More
Global
News / Press Releases
Change of Directors
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 19th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 20, 2024. 1...
Read More
Global
News / Press Releases
Astellas’ XTANDITM (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI can be given alone or in combination with androgen deprivation therapy Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide...
Read More
Global
News / Press Releases
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, “Takeda”), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, “SMBC”) today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The...
Read More

Apr, 2024

Global
News / IR
Posted Financial Results for FY2023
Read More
Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Feb, 2024

Global
News / IR
Posted Financial Results for Q3/FY2023
Read More

Dec, 2023

Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Nov, 2023

Global
News / IR
Posted Financial Results for Q2/FY2023
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom